focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ReNeuron Conditionally Raises GBP17.5 Million Through Placing

Fri, 11th Dec 2020 14:26

(Alliance News) - ReNeuron Group PLC on Friday said it has conditionally raised a total of around GBP17.5 million from a share placing, subscription and open offer first announced in November.

The Wales-based cell-based therapeutics development company conditionally raised total gross proceeds of approximately GBP2.5 million, its intended amount, through the open offer, which provided all qualifying shareholders who did not take part in the placing the chance to participate in a proposed issue of shares at 1 pence each.

ReNeuron intended the subscription to raise gross proceeds of up to GBP1.1 million at a price of 70 pence per share and the share placing to raise gross proceeds of up to GBP13.9 million.

Shares in ReNeuron were 7.7% at 82.40 pence in London on Friday.

The company said the net proceeds of the placing and subscription will allow it "to deliver extended clinical data from its ongoing retinitis pigmentosa phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals."

By Zoe Wickens; zoewickens@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
5 Nov 2012 08:33

Angel Biotech signs new contract with ReNeuron

Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year. The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001

Read more
17 Oct 2012 07:27

ReNeuron progresses stroke clinical trial

ReNeuron has reported further progress in the clinical trial of its ReN001 stem cell therapy for disabled stroke patients, known as the PISCES study. The third and penultimate batch of three patients have all been successfully treated with ReN001 and discharged from hospital with no acute safety is

Read more
11 Sep 2012 14:25

Small caps round-up: ReNeuron, Havelock, Goodwin

Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chi

Read more
14 Aug 2012 12:35

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we m

Read more
28 Jun 2012 14:22

ReNeuron's full-year results disappoint

ReNeuron Group, a UK-based stem cell company, suffered a decline in its share price on Thursday after posting an increase in pre-tax losses for the year ended March 31st. Loss before tax widened from £6.64m to £6.8m year-on-year (y/y), while revenues rose from £0.029m to £0.04m, representing royal

Read more
16 May 2012 15:18

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and impleme

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
3 Apr 2012 12:39

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the seco

Read more
11 Jan 2012 10:55

ReNeuron down despite positive data release

In its second announcement of the year, ReNeuron, the Surrey based stem cell developer, has announced new data on the stability of the company's CTX stem cell line. Researchers from University College London are due to tell a conference in San Diego that the results show "CTX cells retained their m

Read more
3 Jan 2012 08:19

ReNeuron announces positive data

Stem cells therapy developer ReNeuron has gained positive data from a recent pre-clinical study which used its ReN001 stem cell therapy for disabled stroke patients. The newly-published data show significantly improved outcomes in the key behavioural tests in the cell-treated group. A gradual im

Read more
13 Sep 2011 15:09

ReNeuron successfully treats first patient

Stem cells therapy developer ReNeuron has successfully treated a stroke patient who underwent the safe, first-time administration of a higher dose of its new drug, ReN001. The firm ran the increased level of the stem cell therapy drug after the independent Data Safety Monitoring Board recommended t

Read more
13 Dec 2010 18:06

ReNeuron cash call will last two years

Stem cell therapies developer ReNeuron is raising £10m from a share issue at 5.5p a share. The cash will finance the pre-clinical and clinical development costs of the main drug programmes, as well as general running costs, for the next two years. The cash will also be used to complete manufacturi

Read more
12 Jul 2010 08:31

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey. The group said results from the recent resource drilling programme are expected shortly. Managing directo

Read more
12 Jul 2010 07:27

ReNeuron Group To Present New Data Of Lead CTX Stem Cell Line

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN), a clinical-stage stem cell business, said Monday it will present important new data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. MAIN FACTS: -The results of these studies will be pr

Read more
29 Jun 2010 07:51

ReNeuron Group FY Pretax Loss GBP6.2M On Revenue GBP31,000

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN) said Tuesday that for the year ended March 31, it made a pretax loss of GBP6.2 million on revenue of GBP31,000. MAIN FACTS: -Revenue GBP31,000 (2009: GBP93,000) -Operating loss GBP6.2 million (2009: loss GBP4.7 million) -Pretax loss GB

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.